Table 2 Intratumoral studies with different approaches

From: Intratumoral gene therapy versus intravenous gene therapy for distant metastasis control with 2-Diethylaminoethyl-Dextran Methyl Methacrylate Copolymer Non-Viral Vector–p53

Author

Methodology

Subjects

Cancer cells–tissue

Response

Nanoparticles

Carriers

Ref.

Horev-Drori et al.

224Ra-loaded wires plus gemcitabine/5-FU

In vitro/in vivo

Pancreas

√

—

—

77

Xie et al.

64Cu-nanoshells

Nude rats

Head–neck

√

√

Nanoshells

11

Hecht et al.

TNFerade (AdGVEGR.TNF.11D)

Patients

Pancreas

√

—

—

40

Govindarajan et al.

TMAF

In vitro/in vivo

Breast–ovarian

√

—

—

52

Lin et al.

Review

Review

Review

Review

Lipid nanoparticles

Review

33

Zheng et al.

ICG-PL-PEG-mAb

In vitro/in vivo

U87-MG human glioblastoma cancer cells

√

ICG-PL-PEG-mAb

PL-PEG

18

Luo et al.

Core-loaded fibers with hydroxycamptothecin

In vitro/in vivo

H22 hepatoma cells

√

—

Fibers

58

Yang et al.

Hu14.18-IL-2

In vitro/in vivo

NXS2 neuroblastoma cell line

√

—

—

31

Peiris et al.

Three nanoparticle Magnetic chain with doxorubicin

In vitro/in vivo

MAT B III tumor-bearing animals

√

Nanochain magnetic particles

—

56

Hanna et al.

BC-819

In vitro/in vivo

Pancreas

√

—

—

41

Liu et al.

mPEG-PCL-Docetaxel

In vitro/in vivo

H22 hepatoma cells

√

mPEG-PCL

Poly (caprolactone)

57

Luo et al.

PELA Fibers plus hydroxycamptothecin

In vitro/in vivo

H22 hepatoma cells

√

PELA

Poly(D,L-lactide)

58

Geletneky et al.

Parvovirus H-1

in vivo

Glioblastoma multiforme

√

—

—

17

Zhao et al.

NLP-PEG, CLP-PEG plus DOX

In vitro/in vivo

H22 hepatoma cells

√

DOX-NLPs, DOX-CLPs, DOX-NLP-PEG, DOX-CLP-PEG

Cationic liposomes, nano lipid particles

38

Ahmed et al.

Nanoparticles and Thermal ablation

Review

Review

Review

Review

Review

78

Betting et al.

CpG plus rituximab/ cyclophosphamide

In vitro/in vivo

B-cell lymphoma

√

—

—

81

Son et al.

Dendritic cells plus Cyclophosphamide/irradiation

In vitro/in vivo

CT-26 colon carcinoma cell line

√

—

—

79

Raut et al.

Sorafenib

Patients

Refractory sarcomas

√

—

—

80

Li et al.

oHSV-1-NIS

In vitro/in vivo

Prostate

√

—

—

41

Leifler et al.

Adenoviruse carrying TIMP-1 or MMP-9

In vitro/in vivo

Breast

√

—

—

42

Peng et al.

miRNA or shRNA- against target gene (Beclin 1)

In vitro/in vivo

Hepatocellular

√

—

—

43

Weibel et al.

GLV-1h68

In vitro/in vivo

Different tumor models

√

—

—

39

Puntel et al.

HC-Ad-TK/TetOn-Flt3L

In vitro/in vivo

Glioblastoma

√

—

—

43

Hallet et al.

Anti-MMP-9 DNAzyme

In vitro/in vivo

Breast

√

—

—

46

Chen et al.

PDMSCs-PEDF

In vitro/in vivo

Melanoma

√

—

—

44

Xie et al.

Ad-IFN-γ

In vitro/in vivo

Pancreas

√

—

—

34

Kasai et al.

MGH2.1-CPA-CYP2B1 and CPT11-shiCE

In vitro/in vivo

Glioma

√

—

—

50

Ramachandran et al.

HP-NAP, Ad5PTDf35- [Δ24-sNAP]

In vitro/in vivo

Neuroendocrine

√

—

—

49

Huang et al.

shVEGF-DOX-dtACPP

In vitro/in vivo

Glioma

√

dtACPP

—

48

  1. Abbreviations: Ad-IFN-γ, adenovirus-interferon-γ; AdGVEGR.TNF.11D, a replication-deficient adenoviral vector that expresses tumor necrosis factor-α (TNF-α); B16, melanoma cell line; B16F10, murine metastatic melanoma in the tails of C57BL/6 mice; BC-819, a plasmid comprised of the H19 gene regulatory sequences; CLP, cationic liposomes; CT-26, colon carcinoma cell line; DOX, doxorubicin; dtACPP, nanoparticle; FU, fluorouracil; GLV-1h68, Vaccinia virus strain; H22, hepatoma cells; HC-Ad-TK/TetOn-Flt3L, adenoviral vectors encoding cytotoxic herpes simplex type 1 thymidine kinase and the immunostimulatory cytokine fms-like tyrosine kinase ligand 3; HMG-CoA, 3-hydroxy-3-methylglutaryl-coenzyme A; HP-NAP-Ad5PTDf35-[Δ24-sNAP], Helicobacter pylori neutrophil-activating protein, which mediate antitumor effects by recruiting neutrophils and inducing Th1-type differentiation in the tumor microenvironment; HT29, human colon carcinoma cell lines; Hu14.18-IL-2, an immunocytokine consisting of human IL-2 linked to hu14.18 mAb, which recognizes the GD2 disialoganglioside; ICG-PL-PEG-mAb, indocyanine green-polylactic-polyethylene glycol-integrin α(v)β(3) monoclonal antibody; MAT B, animals inoculated with Mat B-III-uPAR cells; MGH2.1, a herpes simplex oncolytic virus type 1 expressing two prodrug-activating transgenes: (a) cyclophosphamide-activating P4502B1 and (b) CPT11-activating secreted human intestinal carboxylesterase; MM9, matrix metalloproteinase-9; mPEG-PCL, poly(caprolactone); NLP, neutral liposomes; NXS2, neuroblastoma cell line; ODN, oligodeoxynucleotide; oHSV-1-NIS, oncolytic herpes simplex virus type 1 with gene coding for human sodium iodide symporter (NIS); PDMSCs-PEDF, placenta-derived mesenchymal stem cells loaded with ecombinant adenoviruses expressing pigment epithelium-derived factor; PEG, polyethylene glycol; PELA, poly(D,L-lactide); PL, polylactic; shVEGF, interfering RNA targeting vascular endothelial growth factor; SLC-Fc, secondary lymphoid tissue chemokine-Fc; TNFerade, a replication-deficient adenoviral vector that expresses tumor necrosis factor-α; TIMP-1, tissue inhibitor of metalloproteinase-9; U-87-MG, human glioblastoma-astrocytoma, epithelial-like cell line.; -
  2. Reproduced with permission from Hohenforst-Schmidt et al.16
Back to article page